Obesity Abstracts

We present the case of a 28-year-old woman who initially presented aged 11 with a brain tumour in 2002. This was diagnosed as a craniopharyngioma and managed with neurosurgery, a ventriculoperitoneal (VP) shunt and radiotherapy. The consequence of this treatment gradually rendered her panhypopituitary and caused hypothalamic injury. Medications which were commenced around this time include hydrocortisone, thyroxine, desmopressin and growth hormone. The hypothalamic insult in t...

Introduction: It is known that bariatric operations cause nutritional deficiencies especially calcium and vitamin D. Reported hypocalcemia after bariatric surgery ranges from 1% after Roux-en-Y gastric bypass (RYGB) to 25% after bilio-pancreatic diversion-duodenal switch. This is mainly the result of bypassing the preferential sites for calcium and vitamin D absorption. Apart from the bariatric operations, hypocalcemia commonly...

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways of d...

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...